Vimarsana
Biggest News Aggregation in the World

Page 20 - Poster Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Presentation Today - Breaking & Trending Today

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL - Vimarsana News

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Florida Cancer Specialists & Research Institute Presents - Vimarsana News

Florida Cancer Specialists & Research Institute Presents

Fort Myers, Florida, June 03, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLS (FCS) physicians are presenting the...

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022 - Vimarsana News

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

/PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of...

Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions - Vimarsana News

Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of...

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022 - Vimarsana News

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

/PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on...